See the success of SPIRIVA® in reducing the risk of exacerbations in your patients like Olivia
image description

Olivia is successful in her business.

See the success of SPIRIVA® in reducing her risk of COPD exacerbations

SPIRIVA® is unsurpassed in risk reduction of moderate-to-severe exacerbations

Ultibro® (glycopyrronium/indacaterol) did not show superiority over SPIRIVA® in reducing moderate-to-severe exacerbations, including severe exacerbations1*

Ultibro® (glycopyrronium/indacaterol) showed no significant difference vs SPIRIVA®†
Ultibro® (n=729) Seebri® (n=739) SPIRIVA®(n=737)
View Callout

*Data presented refer to treatment with once-daily SPIRIVA® 18 µg via HandiHaler®.

GOLD 3 and 4 study population evaluated.1

The 10% reduction in the rate of moderate-to-severe exacerbations with Ultibro® treatment compared with SPIRIVA® 18 µg via HandiHaler® was not significant.1

§Mild exacerbations:
Ultibro® vs Seebri®: 0.85 (0.75, 0.96); p=0.0072
Ultibro® vs SPIRIVA® 18 µg via HandiHaler®: 0.84(0.75, 0.95); p=0.0052

||Moderate or severe exacerbations:
Ultibro® vs Seebri®: 0.88 (0.77, 0.99); p=0.038
Ultibro® vs SPIRIVA® 18 µg via HandiHaler®: 0.90 (0.79, 1.02); p=0.096

Severe exacerbations:
Ultibro® vs Seebri®: 0.81 (0.60, 1.10); p=0.18
Ultibro® vs SPIRIVA® 18 µg via HandiHaler®: 1.16 (0.84, 1.61); p=0.36

#All exacerbations:
Ultibro® vs Seebri®: 0.85 (0.77, 0.94); p=0.0012
Ultibro® vs SPIRIVA® 18 µg via HandiHaler®: 0.86 (0.78, 0.94); p=0.0017

Values are rate reduction (95% CI; p value).

  Source: SPARK trial, sponsored by Novartis AG.
  Ultibro® is a registered trademark of Novartis AG.
  Seebri® is a registered trademark of Novartis AG.

Seebri® (glycopyrronium) showed a higher rate of severe exacerbations (hospitalisations) vs SPIRIVA®1*

Seebri® (glycopyrronium) showed a 43% higher rate of exacerbations vs SPIRIVA®
Ultibro® (n=729) Seebri® (n=739) SPIRIVA® (n=737)
View Callout

*Data presented refer to treatment with once-daily SPIRIVA® 18 µg via HandiHaler®.

GOLD 3 and 4 study population evaluated.1

Mild exacerbations:
Seebri® vs SPIRIVA® 18 µg via HandiHaler®: 0.99 (0.88, 1.12); p=0.90
Ultibro® vs Seebri®: 0.85 (0.75, 0.96); p=0.0072

§Moderate or severe exacerbations:
Seebri® vs SPIRIVA® 18 µg via HandiHaler®: 1.03 (0.91, 1.16); p=0.68
Ultibro® vs Seebri®: 0.88 (0.77, 0.99); p=0.038

||Severe exacerbations:
Seebri® vs SPIRIVA® 18 µg via HandiHaler®: 1.43 (1.05, 1.97); p=0.025
Ultibro® vs Seebri®: 0.81 (0.60, 1.10); p=0.18

All exacerbations:
Seebri® vs SPIRIVA® 18 µg via HandiHaler®: 1.01 (0.91, 1.11); p=0.92
Ultibro® vs Seebri®: 0.85 (0.77, 0.94); p=0.0012

Values are rate reductions (95% CI: p value).

  Source: SPARK trial, sponsored by Novartis AG.
  Ultibro® is a registered trademark of Novartis AG.
  Seebri® is a registered trademark of Novartis AG.

Anoro® (umeclidinium/vilanterol) did not show superiority over SPIRIVA® in reducing the risk of exacerbations2*

Anoro® (umeclidinium/vilanterol) did not show superiority over SPIRIVA® in reducing COPD exacerbations

From the three active-comparator studies, the risk of a COPD exacerbation compared with tiotropium was reduced by 50% in one study (HR=0.5, p=0.044) and was increased by 20% and 90% in two studies (HR=1.2, p=0.709 and HR=1.9, p=0.062, respectively).3

For the primary endpoint, both dosages of umeclidinium/vilanterol demonstrated significant improvements in trough FEV1 over SPIRIVA® 18 µg via HandiHaler® and vilanterol.2

SPIRIVA® demonstrated a lower percentage of patients with COPD exacerbations vs vilanterol and Anoro® 62.5/25 µg in a 24-week study.*

*Data presented refer to treatment with once-daily SPIRIVA® 18 µg via HandiHaler®.

Data displayed based on secondary endpoint. The trial's primary endpoint was trough FEV1 (mean of FEV1 values obtained at 23 h and 24 h after the previous day's dosing) on day 169. GOLD 2-4 study population evaluated.

Trial not powered to show the differences between treatments for exacerbations.
Trial sponsored by GSK.
Anoro® is a registered trademark of the GSK group of companies.

Salmeterol/fluticasone (SFC) propionate did not show superiority over SPIRIVA® in reducing exacerbations4*†‡

Salmeterol/fluticasone propionate showed no significant difference vs SPIRIVA®*

No significant difference between SPIRIVA® and salmeterol/fluticasone propionate was seen for rate of COPD exacerbations in a 2-year study.*

*Data presented refer to treatment with once-daily SPIRIVA® 18 µg via HandiHaler®.

GOLD 3 and 4 study population evaluated.

RR=0.97 (95% CI=0.84, 1.12).

Source: INSPIRE, study sponsored by GSK.

References
1. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199-209. 2. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472-486. 3. Anoro® Ellipta® summary of product characteristics. GlaxoSmithKline; 2014. 4. Wedzicha JA, Calverley PMA, Seemungal TA, et al; for the INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19-26.